Les meilleurs doctors traitant la maladie suivante : Myélome - TOP -75 des médecins

Medical Experience:

- 2024 - Present: Memorial Şişli Hospital  

 Specialist in Internal Medicine and Hematology / Istanbul

- 2017 - 2024: Istanbul Florence Nightingale Hospital  

 Specialist in Internal Medicine and Hematology / Istanbul

- 2015 - 2017: Eskişehir Yunus Emre State Hospital  

 Hematology Specialist - Compulsory Service / Eskişehir

Medical Education:

- 2020 - 2024: Istanbul Florence Nightingale Hospital  

 Demiroğlu Bilim University, Faculty of Medicine / Istanbul, Turkey

- 2017 - 2020: Istanbul Florence Nightingale Hospital  

 Demiroğlu Bilim University, Faculty of Medicine / Istanbul, Turkey

- 2011 - 2015: Eskişehir Osmangazi University, Faculty of Medicine, Department of Hematology / Eskişehir, Turkey

- 2009 - 2011: Harvard University, Faculty of Medicine / Boston, USA

- 2000 - 2008: Ankara University, Faculty of Medicine / Ankara, Turkey

- 1994 - 2000: Ankara University, Faculty of Medicine / Ankara, Turkey

Attended Professional Trainings, Courses, and Conferences:

- European Society for Blood and Marrow Transplantation, 3rd EBMT International Transplant Course, Barcelona, Course, 07.09.2018-09.09.2018 (International)

- Turkish Academy of Blood Science, Lymphoma Masterclass, Istanbul, Course, 01.09.2016-01.03.2017 (National)

- Advanced Life Support Course, Istanbul

Membership in Professional Associations:

- European Society for Blood and Marrow Transplantation

- Turkish Academy of Blood Science

- Advanced Life Support Course

Dr. Toluy Özgümüş has graduated from Istanbul University, Cerrahpaşa Faculty of Medicine in 2008 and completed his internal medicine specialty training at Haydarpaşa Numune Training and Research Hospital between 2009 and 2013. He received his Hematology subspecialty training at Marmara University Hematology Department between 2014-2017; He performed his compulsory service at Kars Harakani State Hospital between 2017-2019. He worked at Sancaktepe Şehit Prof. Dr. Ilhan Varak Training and Research Hospital between 2019-2023.

He is experienced in the field of bleeding and coagulation disorders, especially coagulation disorders (thrombophilia), and has dealt with the diagnosis and treatment of more than 1000 patients. Since he worked in the pandemic hospital of the Anatolian side of Istanbul during the pandemic period, he has extensive experience in the hematological findings of Covid-19 infection and the management of Covid-19 infection in hematological diseases. Hundreds of patient experiences are available in the diagnosis of myeloproliferative diseases such as Polycythemia Vera and Essential Thrombocytosis, in their differentiation from blood cell elevations due to other frequently confused causes, and in their treatment. He has experience in the diagnosis and all treatment processes of rare hematological cancers such as multiple myeloma, acute and chronic leukemias, lymphomas and histiocytosis, as well as bone marrow transplantation.

MEDICAL INTERESTS 

Clotting Disorders (Thrombophilia)

Bleeding Disorders

Myeloproliferative Diseases

Anemias (Anemia)

Acute and Chronic Leukemias

lymphomas

Bone marrow transplantation

Education and Expertise

Ankara University Faculty of Medicine - Medical Education

Gazi University Faculty of Medicine Department of Internal Medicine - Internal Medicine - Specialization

Gazi University Faculty of Medicine Department of Hematology - Hematology - Subspecialty

Duke University Bone Marrow Transplantation Center - Stem Cell Transplantation Training

Fred Hutchinson Cancer Research Center Seattle - Stem Cell Transplant Training

Experience

Duke University-Durham North Carolina Bone marrow transplantation program 2001, cord blood transplant

Fred Hutchinson Cancer Research Center Bone Marrow Transplantation program Seattle 2002, unrelated stem cell transplant

Founder and manager of Gazi University Faculty of Medicine Adult Stem Cell Transplant Unit 2003-2014

Gazi University Faculty of Medicine, Head of Hematology Department 2008-2014

Gazi University Faculty of Health Sciences Dean (founder) 2008-2012

Professional Memberships

Turkish Hematology Association





Bilimsel Yayınları

1.    Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, Craddock C, Finke J, Richard C, Passweg J, Peniket A, Maertens J, Sucak G, Gedde-Dahl T, Vitek A, Nagler A, Blaise D, Beelen D, Maillard N, Schwerdtfeger R, de Witte T, Kroger N. Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT.
    Bone Marrow Transplant. 2017 Jul;52(7):1081. doi: 10.1038/bmt.2017.86
2.    Deger SM, Erten Y, Suyani E, Aki SZ, Ulusal Okyay G, Pasaoglu OT, Pasaoglu H, Arinsoy T, Turkoz Sucak G. Early Diagnostic Markers for Detection of Acute Kidney Injury in Allogeneic Hematopoietic Stem Cell Transplant Recipients. Exp Clin Transplant. 2017 Apr 14. doi: 10.6002/ect.2016.0161. [Epub ahead of print]
3.    Sezer O, Beksac M, Hajek R, Sucak G, Cagirgan S, Linkesch W, Meltem Akay O, Gülbas Z, Nahi H, Plesner T, Snowden JA, Timurağaoğlu A, Dechow T, Lang A, Tuğlular T, Drach J, Armbrecht G, Potamianou A, Couturier C, Olie RA, Feys C, Allietta N, Terpos E. Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study. Br J Haematol. 2017 Jul;178(1):61-71. doi: 10.1111/bjh.14637. Epub 2017 Apr 6
4.    Özkurt ZN, Sucak GT, Akı ŞZ, Yağcı M, Haznedar R.Early Prognostic Value of Monitoring Serum Free Light Chain in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Cancer Invest. 2017 Mar 16;35(3):195-201. 
5.    Aslan D, Türköz-Sucak G, Percy MJ. Recessive congenital methemoglobinemia in immediate generations.Turk J Pediatr. 2016;58(1):113-115
6.    Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, Craddock C, Finke J, Richard C, Passweg J, Peniket A, Maertens J, Sucak G, Gedde-Dahl T, Vitek A, Nagler A, Blaise D, Beelen D, Maillard N, Schwerdtfeger R, de Witte T, Kroger N. Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT. Bone Marrow Transplant. 2017 Feb;52(2):209-215. Erratum in: Bone Marrow Transplant. 2017 Jul;52(7):1081.
7.    Pamukcuoglu M, Acar K, Celik B, Akyurek N, Pepeler MS, Sucak GT. Peripheral and bone marrow CD34+ cell levels on chronic myeloproliferative disease. Hematology. 2017 Mar;22(2):74-80. 
8.    van Gorkom G, Finel H, Giebel S, Pohlreich D, Shimoni A, Ringhoffer M, Sucak G, Schaap N, Dreger P, Sureda A, Schouten HC. Prospective noninterventional study on peripheral blood stem cell mobilization in patients with relapsed lymphomas. J Clin Apher. 2016 Sep 10. doi: 10.1002/jca.21506. [Epub ahead of print]
9.    Necchi A, Miceli R, Bregni M, Bokemeyer C, Berger LA, Oechsle K, Schumacher K, Kanfer E, Bourhis JH, Massard C, Laszlo D, Montoro J, Flechon A, Arpaci F, Secondino S, Wuchter P, Dreger P, Crysandt M, Worel N, Kruger W, Ringhoffer M, Unal A, Nagler A, Campos A, Wahlin A, Michieli M, Sucak G, Donnini I, Schots R, Ifrah N, Badoglio M, Martino M, Raggi D, Giannatempo P, Rosti G, Pedrazzoli P, Lanza F. Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party. Bone Marrow Transplant. 2016 Mar;51(3):384-90. 
10.    Cahu X, Labopin M, Giebel S, Aljurf M, Kyrcz-Krzemien S, Socié G, Eder M, Bonifazi F, Bunjes D, Vigouroux S, Michallet M, Stelljes M, Zuckerman T, Finke J, Passweg J, Yakoub-Agha I, Niederwieser D, Sucak G, Sengeløv H, Polge E, Nagler A, Esteve J, Mohty M; Acute Leukemia Working Party of EBMT. Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. Bone Marrow Transplant. 2016 Mar;51(3):351-7. 
11.    Marchand T, Lamy T, Finel H, Arcese W, Choquet S, Finke J, Huynh A, Irrera G, Karakasis D, Konopacki J, Lambert J, Michieli M, Schouten HC, Schroyens W, Sucak G, Tischer J, Vandenberghe E, Dreger P. Hematopoietic stem cell transplantation for T-cell large granular lymphocyte leukemia: a retrospective study of the European Society for Blood and Marrow Transplantation. Leukemia. 2016 May;30(5):1201-4
12.    Köktürk N, Yıldırım F, Aydoğdu M, Akı ŞZ, Yeğin ZA, Özkurt ZN, Suyanı E, Kıvılcım Oğuzülgen İ, Türköz Sucak G. Is It Possible to Predict Pulmonary Complications and Mortality in Hematopoietic Stem Cell Transplantation Recipients from Pre-Transplantation Exhaled Nitric Oxide Levels? Turk J Haematol. 2016 Mar 5;33(1):34-40. 
13.    Barğı G, Güçlü MB, Arıbaş Z, Akı ŞZ, Sucak GT. Inspiratory muscle training in allogeneic hematopoietic stem cell transplantation recipients: a randomized controlled trial. Support Care Cancer. 2016 Feb;24(2):647-659
14.    Camcıoğlu B, Boşnak-Güçlü M, Karadallı MN, Akı ŞZ, Türköz-Sucak G. The Role of Inspiratory Muscle Training in Sickle Cell Anemia Related Pulmonary Damage due to Recurrent Acute Chest Syndrome Attacks.Case Rep Hematol. 2015;2015:780159. doi: 10.1155/2015/780159. Epub 2015  Apr 28.
15.     Fox CP, Boumendil A, Schmitz N, Finel H, Luan JJ, Sucak G, Blaise D, Finke J, Pflüger KH, Veelken H, Gorin NC, Poiré X, Ganser A, Dreger P, Sureda A. High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in Western patients; a study from the European Society for Blood and Marrow Transplantation. Leuk Lymphoma. 2015 Apr 22:1-20. 
16.    Akı ŞZ, Suyanı E, Cengiz M, Özenirler S, Elbeğ Ş, Paşaoğlu H, Sucak GT. Association between Plasma Endothelin-1, Transforming Growth Factor-β, Fibroblast Growth Factor, and Nitric Oxide Levels and Liver Injury in Hematopoietic Stem Cell Transplantation Recipients with Persistent Iron Overload after Transplantation. Biol Blood Marrow Transplant. 2015 May;21(5):948-953.
17.    Beksaç M, Waage A, Bringhen S, Kristinsson SY, Sucak G, Gimsing P, Giulia L, Tuglular TF, Juliusson G, Turesson I, Palumbo A. Does Low Molecular Weight Heparin Influence The Anti-Myeloma Effects Of Thalidomide? A Retrospective Analysis On Data From The GIMEMA, Nordic and Turkish Myeloma Study Groups Acta Haematologica 2015 Mar 24;133(4):372-380
18.    Pepeler MS, Acar K, Güzel Tunçcan Ö, Uluoğlu Ö, Kalkancı A, Atalar H, Kılıç K, Türköz Sucak G. A proven case of cutaneous rhizopus infection presenting with severe limb pain very soon after induction treatment in a patient with acute lymphoblastic leukemia. Case Rep Hematol. 2015;2015:285360. doi: 10.1155/2015/285360. Epub 2015 Feb 15.
19.    Yegin ZA, Iyidir OT, Demirtaş C, Suyanı E, Yetkin I, Paşaoğlu H, Ilhan C, Sucak GT. The interplay among iron metabolism, endothelium and inflammatory cascade in dysmetabolic disorders. J Endocrinol Invest. 2014 Sep 23. [Epub ahead of print]
20.    Tanase A, Schmitz N, Stein H, Boumendil A, Finel H, Castagna L, Blaise D, Milpied N, Sucak G, Sureda A, Thomson K, Vandenberghe E, Vitek A, Dreger P. Allogeneic and Autologous Stem Cell Transplantation for hepatosplenic T cell lymphoma: A retrospective study of the EBMT Lymphoma Working party. Leukemia. 2014 Sep 19. doi: 10.1038/leu.2014.280. [Epub ahead of print]
21.    Salihoglu A, Elverdi T, Karadogan I, Paydas S, Ozdemir E, Erdem G, Karadurmus N, Akyol G, Kaynar L, Yegin Z, Sucak G, Ozkocaman V, Topcuoglu P, Ozcan M, Birtas E, Göker H, Başlar Z, Ferhanoglu B. Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey. Ann Hematol. 2014 Sep 18. [Epub ahead of print]
22.    Aygencel G, Türkoğlu M, Türköz Sucak G, Benekli M. Prognostic factors in critically ill cancer patients admitted to the intensive care unit. J Crit Care. 2014 Aug;29(4):618-26.
23.    Pamukçuoğlu M, Emmez H, Tunçcan OG, Oner AY, Cırak MY, Senol E, Sucak GT. Brain abscess caused by Nocardia cyriacigeorgica in two patients with multiple myeloma: novel agents, new spectrum of infections. Hematology. 2014 Apr;19(3):158-62. 
24.    Kadir Acar, Şahika Zeynep Akı, Zübeyde Nur Özkurt, Gülendam Bozdayı, Seyyal Rota, Gülsan Türköz Sucak Factors Associated with Cytomegalovirus Reactivation Following Allogeneic Hematopoietic Stem Cell Transplantation: Human Leukocyte Antigens Might Be Among the Risk Factors Turk J Haematol. 2014 Sep 5;31(3):276-285
25.    Abdülkerim Yıldız, Merih Kızıl Çakar, Elif Suyanı, Gülsan Türköz Sucak A Systemic Lupus Erythematosus Patient with Isolated Neutropenia and Diminished Expression of CD55 and CD59 Similar to Paroxysmal Nocturnal Hemoglobinuria doi: 10.4274/Tjh.2013.0318   Pages 323 – 324
26.    Suyanı E, Sucak GT, Akyürek N, Sahin S, Baysal NA, Yağcı M, Haznedar R. Tumor-associated macrophages as a prognostic parameter in multiple myeloma. Ann Hematol. 2013 May;92(5):669-77
27.    Akyol A, Nazlıel B, Batur Caglayan HZ, Oner Y, Sucak GT. Recurrent Transient Ischemic Attacks in a Patient with POEMS Syndrome. Case Rep Neurol Med 2014:158471
28.    Boyacı N, Aygencel G, Turkoglu M, Yegin ZA, Acar K, Sucak GT. The intensive care management process in patients with hematopoietic stem cell transplantation and factors affecting their prognosis. Hematology. 2014 Sep;19(6):338-45
29.    Merve Pamukcuoğlu, Kadir Acar, Nalan Akyürek, Gülsan Türköz Sucak. Non-Leukemic Granulocytic Sarcoma Presenting with Multiple Skin Nodules and a Retroperitoneal Mass. Turk J Hematol 2013;30:81-82
30.    Merve Pamukçuoğlu, Kadir Acar, Nalan Akyürek, Gülsan Türköz Sucak A Rare Case of Acute Leukemia Relapsing with a Granulocytic Sarcoma Causing Ectopic Pregnancy Indian Journal of Hematology and Blood Transfusion April 2013
31.    Keser I, Suyani E, Aki SZ,  Sucak AG. The positive impact of regular exercise program on stem cell mobilization prior to autologous stem cell transplantation. Transfus Apher Sci. 2013 Jul 6. doi:pii: S1473-0502(13)00205-X. 10.1016/j.transci.2013.06.007. [Epub ahead of print]
32.    Buyukasik Y, Acar K, Kelkitli E, Uz B, Serefhanoglu S, Ozdemir E, Pamukcuoglu M, Atay H, Bektas O, Sucak GT, Turgut M, Aksu S, Yagci M, Sayınalp N, Ozcebe OI, Goker H, Haznedaroglu IC.  Hyper-CVAD Regimen in Routine Management of Adult Acute Lymphoblastic Leukemia: A Retrospective Multicenter Study. Acta Haematol 2013 Jun 19;130(3):199-205.
33.    Yaşar DG, Suyanı E, Özenirler S, Sucak GT. Adefovir is effective to promote development of immunity to donor origin hepatitis B virus in an allogeneic transplant recipient: a case report.Transplant Proc. 2013 Mar;45(2):833-4.
34.    Keser I, Suyani E, Yosmaoglu HB, Aki SZ, Sucak AG. Acute physiological responses to physiotherapy applications pre and post autologous stem cell transplantation: an experimental study. Hematology. 2014 Apr;19(3):136-40.
35.    Yağcı M, Yegin ZA, Akyürek N, Kayhan H, Ozkurt ZN, Sucak GT, Haznedar R. TCTP/HRF pathway and angiogenesis: a feasible intercourse in chronic lymphocytic leukemia. Leuk Res. 2013 Jun;37(6):665-70.
36.    Sucak GT, Cakar MK, Suyanı E, Akı Z, Altındal SE, Acar K. Outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin lymphoma patients in a centre from Turkey. Hematology. 2013 Sep;18(5):269-76.
37.    Türkoğlu M, Erdem GU, Suyanı E, Sancar ME, Yalçın MM, Aygencel G, Akı Z, Sucak G.Acute respiratory distress syndrome in patients with hematological malignancies. Hematology. 2013 May;18(3):123-130.
38.    Rovó A, Aljurf M, Chiodi S, Spinelli S, Salooja N, Sucak G, Hunter A, Kim TS, Socié G, van Lint MT, Passweg JR, Arat M, Badoglio M, Tichelli A. Paternity wishes in long-term survivors after allogeneic hematopoietic SCT. A study of the late effects working party of the EBMT. Bone Marrow Transplant. 2013 Jun;48(6):878-9.
39.    Çakar MK, Suyani E, Sucak GT, Altindal Ş, Aki SZ, Acar K, Yağci M, Rota S, Özenirler S. HBV-related events after allogeneic hematopoetic stem cell transplantatıon in a center from Turkey. Ann Hematol. 2013 Mar;92(3):395-402.
40.    Akı ŞZ, Suyanı E, Bildacı Y, Çakar MK, Baysal NA, Sucak GT. Prognostic role of pre-transplantation serum C-reactive protein levels in patients with acute leukemia undergoing myeloablative allogeneic stem cell transplantation. Clin Transplant. 2012 Sep-Oct;26(5):E513-2.
41.    Akı SZ, Pamukçuoğlu M, Bağrıaçık Ü, Sucak GT. Encephalopathy: an unusual neurologic complication of autologous hematopoietic stem cell transplant in patients with multiple myeloma with renal failure.Leuk Lymphoma. 2013 Apr;54(4):894-6.
42.    Rovó A, Aljurf M, Chiodi S, Spinelli S, Salooja N, Sucak G, Hunter A, Kim TS, Socié G, van Lint MT, Passweg JR, Arat M, Badoglio M, Tichelli A; Late Effects Working Party of the EBMT. Ongoing graft-versus-host disease is a risk factor for azoospermia after allogeneic hematopoietic stem cell transplantation: a survey of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2013 Mar;98(3):339-45.
43.    Palumbo A, Waage A, Hulin C, Beksac M, Zweegman S, Gay F, Gimsing P, Leleu X, Wijermans P, Sucak G, Pezzatti S, Juliusson G, Pégourié B, Schaafsma M, Galli M, Turesson I, Kolb B, van der Holt B, Baldi I, Rolke J, Ciccone G, Wetterwald M, Lokhorst H, Boccadoro M, Rodon P, Sonneveld PSafety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. Haematologica. 2013 Jan;98(1):87-94.
44.    Aydoğdu M, Ozyilmaz E, Köktürk N, Yeğin ZA, Özkurt ZN, Aki ZS, Sucak G. Is there any relationship between pulmonary function tests and post-transplant complications of allogeneic hematopoetic stem cell transplantation? Minerva Med. 2012 Jun;103(3):189-98.
45.    Suyanı E, Altındal Ş, Akı Ş, Sucak GT. Does fludarabine increase the incidence of sinusoidal obstruction syndrome when combined with Bu/Cy during conditioning? Clin Transplant. 2012 Mar-Apr;26(2):E85-6.
46.    Sucak GT, Yaşar DG, Yegin ZA, Ergün MA, Ozkurt ZN, Aki ŞZ, Güntekin S. The prognostic role of hemochromatosis H63D allele in allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2012 Aug;91(8):1281-7.
47.    Suyanı E, Sucak GT, Erten Y, Cakar MK, Ulusal G, Yağcı M, Haznedar R. Evaluation of multiple myeloma patients presenting with renal failure in a university hospital in the year 2010. Ren Fail. 2012;34(2):257-62.
48.    Sucak GT, Suyanı E, Baysal NA, Altındal Ş, Çakar MK, Akı ŞZ, Yeğin ZA, Şanlıer N.The role of body mass index and other body composition parameters in early post-transplant complications in patients undergoing allogeneic stem cell transplantation with busulfan-cyclophosphamide conditioning. Int J Hematol. 2012 Jan;95(1):95-101.
49.    Bağrıaçık EU, Yaman M, Haznedar R, Sucak G, Delibasi T. TSH-induced gene expression involves regulation of self-renewal and differentiation-related genes in human bone marrow-derived mesenchymal stem cells.J Endocrinol. 2012 Feb;212(2):169-78.
50.    Elif Suyanı, Zeynep Akı, Zeynep Arzu Yeğin, Gülsan Türköz Sucak. Bortezomib-Associated Severe Orthostatic Hypotension and Hyponatremia Turk J Hematol 2012; 29: 301-302.
51.    Zeynep Arzu Yegin, Gülsan Türköz Sucak, Gonca Erbaş, Münci Yağcı ARA-C associated pulmonary toxicity. Turk J Hematol 2011; 28: 81-3.
52.    Turkoglu M, Mirza E, Tunçcan OG, Erdem GU, Dizbay M, Yağcı M, Aygencel G, Türköz Sucak G. Acinetobacter baumannii infection in patients with hematologic malignancies in intensive care unit: risk factors and impact on mortality. J Crit Care. 2011 Oct; 26(5):460-7.
53.    Akı SZ, Paşaoğlu H, Yeğin ZA, Suyanı E, Demirtaş CY, Ozkurt ZN, Yağcı M, Sucak GT. Impact of prohepcidin levels and iron parameters on early post-transplantation toxicities.Hematology. 2011 Sep;16(5):284-90.
54.    Yenicesu I, Sucak G, Dilsiz G, Akı SZ, Yeğin ZA. Hematopoietic stem cell transplantation in a very high risk group of patients with the support of granulocyte transfusion. Indian J Hematol Blood Transfus. 2011 Sep;27(3):146-51.
55.    Tunçcan ÖG, Aki ŞZ, Akyürek N, Sucak G, Şenol E. Isolated cutaneous aspergillosis in an acute lymphoblastic leukemia patient after allogeneic stem cell transplantation.J Infect Dev Ctries. 2011 May 28;5(5):406-9.
56.    Rota S, Fidan K, Bozdayı G, Dalgıç A, Fidan I, Sucak G, Müderris T. [Investigation of BK and JC virus DNA positivities by real-time polymerase chain reaction in the clinical samples of patients with high risk].Mikrobiyol Bul. 2011 Apr;45(2):280-7.
57.    Suyanı E, Yağcı M, Sucak GT. Complete remission with a combination of lenalidomide, cyclophosphamide and prednisolone in a patient with incomplete POEMS syndrome. Acta Haematol. 2011;126(4):199-201.
58.    Sucak GT, Özkurt ZN, Suyanı E, Yaşar DG, Akdemir ÖÜ, Akı Z, Yeğin ZA, Yağcı M, Kapucu ÖL. Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival. Ann Hematol. 2011 Nov;90(11):1329-36.
59.    Ljungman P,  de la Camara R, Perez-Bercoff L, Abecasis M, Nieto Campuzano JB, Cannata-Ortiz MJ, Cordonnier C, Einsele H, Gonzalez-Vicent M, Espigado I, Halter J, Martino R, Mohty B, Sucak G, Ullmann AJ, Vázquez L, Ward KN, Engelhard D; Infectious Diseases Working Party, European Group for Blood and Marrow Transplantation; Infectious Complications Subcommittee, Spanish Group of Haematopoietic Stem-cell Transplantation. Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients. Haematologica. 2011 Aug;96(8):1231-5.
60.    Sucak GT, Aki SZ, Yüzbaşioğlu B, Akyürek N, Yağci M, Bağriaçik U, Haznedar R. Prognostic value of bone marrow microvessel density and angiogenic cytokines in patients with multiple myeloma undergoing autologous stem cell transplant. Leuk Lymphoma. 2011 Jul;52(7):1281-9.
61.    Yegin ZA, Paşaoğlu H, Aki SZ, Özkurt ZN, Demirtaş C, Yağci M, Acar K, Sucak GT. Pro-oxidative/antioxidative imbalance: a key indicator of adverse outcome in hematopoietic stem cell transplantation.Int J Lab Hematol. 2011 Aug;33(4):414-23.
62.    Haznedar R, Akı ŞZ, Akdemir ÖÜ, Özkurt ZN, Çeneli O, Yağcı M, Sucak GT, Unlü M. Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging. 2011 Jun;38(6):1046-53.
63.    Suyani E, Aki Z, Güzel Ö, Altindal S, Senol E, Sucak G.H1N1 infection in a cohort of hematopoietic stem cell transplant recipients: prompt antiviral therapy might be life saving.Transpl Infect Dis. 2011 Apr;13(2):208-12.
64.    Sucak A, Acar K, Celen S, Danisman N, Sucak GT. Outcome of pregnancies in women with thrombophilic disorders.J Obstet Gynaecol. 2010;30(8):847-51.
65.    Suyanı E, Sucak GT, Akı ŞZ, Yeğin ZA, Özkurt ZN, Yağcı M. Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT. Ann Hematol. 2011 Jun;90(6):685-91.
66.    Beksaç M, Haznedar R, Firatli-Tuğlular T, Özdogu H, AydoĞdu I, Konuk N, Sucak G, Kaygusuz I, Karakus S, Kaya E, Ali R, Gulbas Z, Ozet G, Goker H, Undar L. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol. 2011 Jan;86(1):16-22.
67.    Sucak G, Suyanı E, Özkurt ZN, Yeğin ZA, Aki Z, Yagci M. Abnormal protein bands in patients with multiple myeloma after haematopoietic stem cell transplantation: does it have a prognostic significance? Hematol Oncol. 2010 Dec;28(4):180-4.
68.    Ozyilmaz E, Aydoğdu M, Sucak G, Akı ŞZ, Özkurt ZN, Yeğin ZA, Köktürk N. Risk factors for fungal pulmonary infections in hematopoietic stem cell transplantation recipients: the role of iron overload. Bone Marrow Transplant. 2010 Oct;45(10):1528-33.
69.    Tunçcan OG, Yegin ZA, Ozkurt ZN, Erbaş G, Akı SZ, Senol E, Yağcı M, Sucak G. High ferritin levels are associated with hepatosplenic candidiasis in hematopoietic stem cell transplant candidates.Int J Infect Dis. 2010 Sep;14 Suppl 3:e 104-7.

Le docteur Dror Levin est pédiatre principal et directeur des départements de traitement des troubles sanguins et des cancers des os (sarcomes) à l'hôpital pour enfants "Dana" et au centre médical "Sourasky", respectivement. Il est spécialiste en médecine pédiatrique, en hématologie et en oncologie, et a également étudié à l'étranger à l'Institut orthopédique Rizzoli en Italie.

Hematology

Fields of Study and Interests

• Approach to Anemia

• lymphomas

• Multiple Myeloma

• Myeloproliferative Diseases

• thrombocytopenia

• Bleeding Diathesis

• Approach to lymphadenopathy/ splenomegaly

• Acute Leukemias

• Chronic Leukemias

• Approach to Anemia

• lymphomas

• Multiple Myeloma

• Myeloproliferative Diseases

• thrombocytopenia

• Bleeding Diathesis

• Approach to lymphadenopathy/ splenomegaly

• Acute/ Chronic Leukemias

Education

• Undergraduate Istanbul Faculty of Medicine Istanbul University 2007

• Master's Degree Internal Medicine USA Marmara University Faculty of Medicine 2012

PhD Hematology Clinic Istanbul Training and Research Hospital 2018

• Associate Professor Hematology Clinic Prof.Dr.Cemil Taşçıoğlu Training and Research Hospital

2019

Career

• Assistant Dr. Istanbul University Cerrahpaşa Faculty of Medicine General Surgery / USA 2007-

2008

• Assistant Dr. Marmara University Faculty of Medicine Internal Medicine USA 2008-2012

• Expert Dr. Mardin Derik State Hospital 2013-2015

• Minor Assistant Dr. Istanbul Training and Research Hospital Hematology Clinic 2015-2018

• Expert Dr. Prof. Dr. Cemil Taşçıoğlu Training and Research Hospital Hematology Clinic 2018-2019

• Associate Professor Prof. Dr. Cemil Taşçıoğlu Training and Research Hospital Hematology Clinic

2019-2020

• Associate Professor Istanbul Başakşehir Çam and Sakura City Hospital Hematology Clinic 2020

• Associate Professor Bozyaka Training and Research Hospital Hematology Clinic 2020-2021

• Associate Professor Istinye University Faculty of Medicine, Department of Internal Medicine, Liv

Vadistanbul Hospital 2021-2023

Publications: Eren R, Doğu MH, Emir S, Huq GE, Okçu O, Altındal Ş, Yokuş O, Suyanı E.

Rethinking the usefulness of bone marrow biopsy on treatment decision in CLL patients at

Wolfgang Johannes Köstler est un spécialiste certifié en médecine interne, hématologie/oncologie et médecine des soins intensifs, spécialisé en hématologie et oncologie interne, médecine des soins intensifs. Il est l'un des spécialistes du cancer du sein et du sarcome les mieux classés et possède une vaste expérience dans ce domaine. Il est diplômé de l'Université médicale de Vienne et de l'Institut scientifique Weizmann. Il a également suivi une formation spéciale au Memorial Sloan-Kettering Cancer Center et au Royal Prince Alfred Hospital.

Le professeur Drach est spécialiste en oncologie et titulaire d'un doctorat de l'université médicale de Vienne. Il a de l'expérience dans les domaines de la recherche, de la médecine interne, de l'oncologie hématologique, de la nutrition et du mode de vie dans le cancer. Il est directeur de la clinique privée Josefstadt à Vienne et membre du conseil d'administration de la Société autrichienne d'hématologie et d'oncologie. Il a publié plus de 120 articles scientifiques et donné plus de 200 conférences/présentations.

Education:

2015

Dokuz Eylül University, Medical Faculty, Internal Medicine and Hematology 

2010

Dokuz Eylül University, Medical Faculty, Internal Medicine 

2005

Hacettepe University, Medical Faculty,

Experience:

2024 – 

Istanbul Florence Nightingale Hospital

2017 – 2024

Bağcılar Medipol University Hospital

2017 – 2017

Fırat University

2015 - 2017

Fırat University

2014 - 2015

Mayo Clinic

Publications:

18 Articles Published in International Peer-Reviewed Journals

26 Abstracts and Books Presented at International Scientific Conferences

7 Articles Published in National Peer-Reviewed Journals

51 Abstracts Presented at National Scientific Conferences

Kodchanut Litleaungdej, M.D.